We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05422053
Recruitment Status : Completed
First Posted : June 16, 2022
Last Update Posted : January 19, 2023
Sponsor:
Information provided by (Responsible Party):
Tandem Diabetes Care, Inc.

Tracking Information
First Submitted Date  ICMJE June 13, 2022
First Posted Date  ICMJE June 16, 2022
Last Update Posted Date January 19, 2023
Actual Study Start Date  ICMJE June 29, 2022
Actual Primary Completion Date January 6, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 13, 2022)
  • Severe Hypoglycemic Events [ Time Frame: 3 months ]
    Severe hypoglycemia (with cognitive impairment such that assistance of another individual is needed for treatment) during study compared with data on severe hypoglycemic events reported by T1D Exchange clinic registry over a 3-month time period
  • Diabetic ketoacidosis [ Time Frame: 3 months ]
    DKA event rate
  • Adverse device effects [ Time Frame: 3 months ]
    Number of unanticipated adverse device effects
  • Other serious adverse events [ Time Frame: 3 months ]
    Number of other serious adverse events
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: June 13, 2022)
  • Adverse events [ Time Frame: 3 months ]
    Number of Adverse events
  • Glucose < 54 mg/dL [ Time Frame: 3 months ]
    Percent time CGM glucose < 54 mg/dL
  • Glucose < 70 mg/dL [ Time Frame: 3 months ]
    Percent time CGM glucose < 70 mg/dL
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: June 13, 2022)
  • Glucose time in range 70-180 mg/dL [ Time Frame: 3 months ]
    Percent time CGM glucose in range 70-180 mg/dl
  • Glucose > 180 mg/dL [ Time Frame: 3 months ]
    Percent time CGM glucose > 180 mg/dL
  • Glucose > 250 mg/dL [ Time Frame: 3 months ]
    Percent time CGM glucose > 250 mg/dL
  • Glucose time in range 70-140 mg/dL [ Time Frame: 3 months ]
    Percent time CGM glucose in range 70-140 mg/dl
  • CGM mean glucose [ Time Frame: 3 months ]
    CGM-measured mean glucose (mg/dL)
  • Coefficient of Variation [ Time Frame: 3 months ]
    CGM measured glucose variability measured with the coefficient of variation (mg/dL)
  • Standard Deviation [ Time Frame: 3 months ]
    CGM measured glucose variability measured with the standard deviation (mg/dL)
  • Hemoglobin A1c [ Time Frame: 3 months ]
    Change in Hemoglobin A1c from baseline
  • CGM Metrics by Time of Day [ Time Frame: 3 months ]
    All CGM metrics listed above (percent time) for: All 24 hours of the day, Daytime only (06:00AM to 00:00AM), Nighttime only (00:00AM to 06:00AM)
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)
Official Title  ICMJE Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)
Brief Summary A prospective, single-arm study of 13 weeks of home use of the t:slim X2 insulin pump with Control-IQ technology in individuals with type 1 diabetes who will plan to use at least one basal rate > 3 units/hr.
Detailed Description The objectives of the study are to assess safety and explore glycemic outcomes with use of an automated insulin dosing (AID) system (t:slim X2 insulin pump with Control-IQ technology v1.5) in adults with type 1 diabetes who will plan to use at least one basal rate > 3 units/hr. Up to 60 participants may be recruited.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Type 1 Diabetes
Intervention  ICMJE Device: t:slim X2 insulin pump with Control-IQ technology 1.5
t:slim X2 insulin pump with Control-IQ technology 1.5, and wearing the Dexcom G6 CGM.
Study Arms  ICMJE Experimental: t:slim X2 insulin pump with Control-IQ technology
Adults with type 1 diabetes will use the t:slim X2 insulin pump with Control-IQ technology 1.5 for 3-months of outpatient use. Meal and exercise challenges will be performed.
Intervention: Device: t:slim X2 insulin pump with Control-IQ technology 1.5
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 18, 2023)
34
Original Estimated Enrollment  ICMJE
 (submitted: June 13, 2022)
60
Actual Study Completion Date  ICMJE January 6, 2023
Actual Primary Completion Date January 6, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age ≥ 18 years
  • Diagnosis of type 1 diabetes for at least 1 year
  • Currently using an insulin pump (of any brand) for at least 3 months, and will plan to use at least one basal rate above 3 units/hr with the study pump
  • HbA1c < 10.5%
  • Weight ≤ 200 kg
  • Residing full-time in the United States, with no anticipated travel outside the United States during the period of study participation.
  • Participant has agreed to participate in the study; and has read, understood and signed the informed consent form (ICF); and has agreed to follow all study procedures, including suspending use of any personal CGM for the duration of the clinical trial once the study CGM is in use.
  • Willing to use only aspart (novolog) or lispro (humalog) insulin with the study pump, with no use of concentrated insulin above U-100, long-acting basal insulin injections, or inhaled insulin with the study pump.
  • Have current glucagon product to treat severe hypoglycemia (injectable or nasal) at home (will provide prescription if they do not have one)
  • Willing and able to perform the study exercise and meal challenges.
  • Have a care partner, trained in hypoglycemia and hyperglycemia treatment guidelines, present during the challenges and until the next day.
  • Investigator has confidence that the participant can successfully operate all study devices and is capable of adhering to the protocol, including ability to respond to alerts and alarms, and to provide basic diabetes self-management.

Exclusion Criteria:

  • More than 1 episode of diabetic ketoacidosis (DKA) in the past 6 months
  • More than 1 episode of severe hypoglycemia (needing assistance) in the past 6 months
  • Inpatient psychiatric treatment in the past 6 months
  • History of drug abuse (defined as any illicit drug use) or history of alcohol abuse prior to screening or unwillingness to agree to abstain from illicit drugs throughout the study.
  • For Female: Currently pregnant or planning to become pregnant during the time period of study participation
  • Use of sulfonylureas, meglitinides or other medications specifically listed in protocol or determined by investigator to interfere with the study
  • Unstable dose of SGLT-2 inhibitor, GLP-1 receptor agonist, or DPP-4 inhibitor as listed in the protocol, or starting a new non-insulin glucose lowering or weight loss agent during the trial
  • Hemophilia or any other bleeding disorder
  • History of heart, liver, lung or kidney disease determined by investigator to interfere with the study
  • History of allergic reaction to Humalog or Novolog
  • Use of glucocorticoids or other medications determined by investigator to interfere with study
  • Abnormal screening electrocardiogram consistent with increased risk during study exercise activities, such as arrhythmia, ischemia, or prolonged QTc interval. Investigator will review all electrocardiograms
  • Significant chronic kidney disease (which could impact CGM accuracy in investigator's judgment) or hemodialysis
  • History of adrenal insufficiency
  • History of abnormal TSH consistent with hypothyroidism or hyperthyroidism that is not appropriately treated
  • History of gastroparesis
  • A condition, which in the opinion of the investigator or designee, would put the participant or study at risk
  • Participation in another pharmaceutical or device trial at the time of enrollment or anticipated for during the time period of study participation
  • Employed by, or having immediate family members employed by Tandem Diabetes Care, Inc., or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT05422053
Other Study ID Numbers  ICMJE TP-0009856
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Tandem Diabetes Care, Inc.
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Tandem Diabetes Care, Inc.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Jordan Pinsker, MD Tandem Diabetes Care
PRS Account Tandem Diabetes Care, Inc.
Verification Date January 2023

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP